-
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
-
Merus N.V. (MRUS) PT Raised to $38 at Citi After MCLA Data Impresses in Small Population
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
UPDATE: Citi Upgrades Merus N.V. (MRUS) to Buy, 'Turn-Around Story in Zeno is Working'
-
Merus N.V. (MRUS) Prices 4.75M Share Common Offering at $14.50/Sh
-
Merus Announces Pricing of Public Offering of Common Shares
-
Merus Announces Pricing of Public Offering of Common Shares
-
Merus N.V. (MRUS) Announces $60M Proposed Underwritten Public Offering of Common Shares
-
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
-
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
-
Merus N.V. (MRUS) PT Lowered to $16 at Citi
-
Merus N.V. (MRUS) PT Lowered to $16 at Citi
-
Merus N.V. (MRUS) Model Update At Citi Takes $1 Out Of EPS
-
Merus to Participate in Citi’s 13th Annual Biotech Conference
-
Merus to Participate in Citi’s 13th Annual Biotech Conference
-
Merus to Participate in Two Investor Conferences in September 2017
-
Merus N.V. (MRUS) PT Lowered to $19 at Citi
-
Merus N.V. (MRUS) Down 5% on Citi Downgrade to Neutral
-
Citi Downgrades Merus N.V. (MRUS) to Neutral
-
Citi Upgrades Merus N.V. (MRUS) to Buy
-
Citi Downgrades Merus N.V. (MRUS) to Neutral
-
Merus to Participate in Upcoming Investor Conferences
-
Citi Starts Merus N.V. (MRUS) at Buy
-
Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
-
Merus N.V. Announces Closing of Initial Public Offering
-
Merus B.V. (MRUS) IPO Opens Modestly Lower
-
Merus (MRUS) Prices 5.5M Common Stock IPO at $10/Share
-
Merus Announces Pricing of Initial Public Offering